Cell-based Assay

Cell-based Assay encompasses experimental methods utilising living cells to measure biological processes, drug effects, toxicity, or functional activities, providing physiologically relevant models more predictive of in vivo responses compared to cell-free biochemical assays. These assays evaluate diverse endpoints including cell viability, proliferation, apoptosis, receptor activation, signal transduction, gene expression, protein secretion, or complex phenotypic changes within intact cellular environments maintaining native protein conformations, compartmentalisation, and regulatory mechanisms.

The pharmaceutical industry relies extensively on cell-based assays throughout drug discovery and development. High-throughput screening campaigns employ cell-based readouts identifying compounds modulating specific pathways or phenotypes, while secondary assays confirm mechanisms and assess selectivity. Safety pharmacology uses specialised cell lines evaluating cardiac toxicity through hERG channel assays, hepatotoxicity using primary hepatocytes, and phototoxicity employing keratinocyte systems. Biologic characterisation requires cell-based potency assays demonstrating therapeutic proteins engage targets and trigger intended biological responses. Regulatory agencies increasingly require cell-based assays as product release specifications, particularly for complex biologics. Advanced technologies incorporate high-content imaging analysing multiple cellular features simultaneously, biosensors reporting real-time signalling dynamics, and automated platforms improving throughput and reproducibility. As in vitro models advance through induced pluripotent stem cell-derived systems, organoids, and microphysiological platforms, cell-based assays become increasingly sophisticated, enabling better predictions of human responses while reducing animal testing.